Published • loading... • Updated
GLP-1 meds linked to lower diabetes, heart risks than standard diabetes prevention medication
In a study of more than 256,000 adults, GLP-1 injections also cut death risk by 41% and lowered heart attack and stroke rates versus metformin.
- A study of 256,492 adults with prediabetes and obesity found GLP-1 medications reduced type 2 diabetes risk by 31 percent compared to metformin, according to findings set for presentation Friday at the American Heart Association's Scientific Sessions 2026 in Chicago.
- Patients on GLP-1 medications were 50 percent more likely to restore normal blood sugar levels than those taking metformin. Researchers analyzed records from the TriNetX global health network, comparing treatment outcomes in adults averaging 52 years old.
- Users of GLP-1 medications experienced a 41 percent lower risk of death from any cause and 15 percent fewer heart attacks, 20 percent fewer strokes, and 25 percent fewer heart failure cases than metformin users.
- While encouraging, endocrinologist Bradley Neutel of Coastline Endocrinology cautioned that observational studies cannot prove causation. He noted that lifestyle factors and healthcare access may differ between groups, making the results less definitive than randomized trials.
- Study leader Dr. Vinicius de Sousa Barzon Serra of the Mayo Clinic suggested prediabetes may be an appropriate time to discuss GLP-1 medications with certain patients. However, metformin remains a safe, inexpensive first-line treatment, and cost and access barriers persist for newer drugs.
Insights by Ground AI
11 Articles
11 Articles
Popular weight-loss drugs may prevent prediabetes from turning into diabetes - NEW YORK TIMES POST
NEWYou can now listen to Fox News articles! Adults with prediabetes and obesity who took GLP-1-based medications had a 31% lower risk of developing type 2 diabetes and a 41% lower risk of death compared with those taking metformin. Metformin is an oral medication used primarily to treat type 2 diabetes, widely considered the first-line [...]
Study links GLP-1 drugs to 31% lower type 2 diabetes risk than metformin—but researchers caution the findings are preliminary
Adults with prediabetes and obesity who took GLP-1 drugs had lower risks of type 2 diabetes and cardiovascular events than metformin users, though the observational findings remain preliminary.
Coverage Details
Total News Sources11
Leaning Left0Leaning Right5Center5Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
